Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.64 |
| ▸ | CDK2 | P24941 | 7/20 | 0.50 |
| ▸ | IGF1R | P08069 | 3/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 2/20 | 0.43 |
| ▸ | CDK4 | P11802 | 2/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.42 |
| ▸ | JUN | P05412 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700954 | 0.87 | CDK2 (0.54) | HDAC1CDK2IGF1RMAPK8MAPK9 | |
| SCHEMBL699854 | 0.85 | HDAC1 (0.65) | HDAC1CDK2CDK1CDK4 | |
| SCHEMBL12790886 | 0.84 | PKM (0.58) | HDAC1HDAC2 | |
| SCHEMBL699310 | 0.83 | HDAC1 (0.78) | HDAC1CDK2IGF1RHDAC2CDK1 | |
| SCHEMBL701827 | 0.83 | HDAC1 (0.51) | HDAC1CDK2IGF1RMAPK8MAPK9 | |
| SCHEMBL12791204 | 0.81 | HDAC1 (0.49) | HDAC1HDAC2 | |
| SCHEMBL273614 | 0.81 | CDK2 (0.53) | CDK2MAPK8MAPK9CDK1CDK4 | |
| SCHEMBL699239 | 0.81 | HDAC1 (0.69) | HDAC1CDK2IGF1RHDAC2CDK1 | |
| SCHEMBL12790887 | 0.80 | HDAC1 (0.45) | HDAC1HDAC2 | |
| SCHEMBL12791297 | 0.80 | HDAC1 (0.45) | HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | claimed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | HDAC1 1/4885CDK2 16/4885IGF1R 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.